Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
SIVEXTRO
Overview
What is SIVEXTRO?
SIVEXTRO (tedizolid phosphate), a phosphate prodrug, is converted to tedizolid in the presence of phosphatases.
Tedizolid phosphate has the chemical name [(5)-(3-{3-Fluoro-4-[6-(2-methyl-2-tetrazol- 5-yl) pyridin-3-yl]phenyl}-2-oxooxazolidin- 5-yl]methyl hydrogen phosphate.
Its empirical formula is CHFNOP and its molecular weight is 450.32. Its structural formula is:
Tedizolid phosphate is a white to yellow solid and is administered orally or by intravenous infusion.
The pharmacologically active moiety, tedizolid, is an antibacterial agent of the oxazolidinone class.
SIVEXTRO tablets contain 200 mg of tedizolid phosphate, and the following inactive ingredients: microcrystalline cellulose, mannitol, crospovidone, povidone, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol/macrogol, talc, and yellow iron oxide.
SIVEXTRO for injection is a sterile, white to off-white sterile lyophilized powder for injection in single-use vials of 200 mg. The inactive ingredients are mannitol (105 mg), sodium hydroxide, and hydrochloric acid, which is used in minimal quantities for pH adjustment.
What does SIVEXTRO look like?
What are the available doses of SIVEXTRO?
SIVEXTRO 200 mg tablet is a yellow film-coated oval tablet; each tablet is debossed with "TZD" on one side and "200" on the other side.
SIVEXTRO for injection is a sterile, white to off-white lyophilized powder for injection in single-use vials of 200 mg. Each 200 mg vial must be reconstituted with Sterile Water for Injection and subsequently diluted only with 0.9% Sodium Chloride Injection, USP.
What should I talk to my health care provider before I take SIVEXTRO?
How should I use SIVEXTRO?
SIVEXTRO is an oxazolidinone-class antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), , , Group (including , , and ), and .
The recommended dosage of SIVEXTRO is 200 mg administered once daily for six (6) days either orally (with or without food) or as an intravenous (IV) infusion in patients 18 years of age or older.
The recommended dosage and administration is described in Table 1.
No dose adjustment is necessary when changing from intravenous to oral SIVEXTRO.
If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose.
What interacts with SIVEXTRO?
Sorry No Records found
What are the warnings of SIVEXTRO?
Sorry No Records found
What are the precautions of SIVEXTRO?
Sorry No Records found
What are the side effects of SIVEXTRO?
Sorry No records found
What should I look out for while using SIVEXTRO?
None
What might happen if I take too much SIVEXTRO?
In the event of overdosage, SIVEXTRO should be discontinued and general supportive treatment given. Hemodialysis does not result in meaningful removal of tedizolid from systemic circulation.
How should I store and handle SIVEXTRO?
SIVEXTRO tablets and SIVEXTRO for injection should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917Furosemide Injection, USP 10 mg/mL is supplied as follows:Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]Do not use if solution is discolored or contains particulate.Protect from light. Do not remove the Ansyr syringe from carton until ready to use.Discard unused portion.Revised: 5/2016 EN-4309Hospira, Inc., Lake Forest, IL 60045 USA Repackaged by:Cardinal HealthZanesville, OH 43701L35119120917
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Tedizolid phosphate is the prodrug of tedizolid, an antibacterial agent [].
Non-Clinical Toxicology
NoneFurosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination.
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly. In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.
Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure. An interruption or reduction in the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary.
Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
Furosemide may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively.
Simultaneous administration of sucralfate and Furosemide Injection may reduce the natriuretic and antihypertensive effects of furosemide. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least 2 hours.
In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Use of furosemide concomitantly with chloral hydrate is therefore not recommended.
Phenytoin interferes directly with renal action of furosemide. There is evidence that treatment with phenytoin leads to decrease intestinal absorption of furosemide, and consequently to lower peak serum furosemide concentrations.
Methotrexate and other drugs that, like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide. Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of both furosemide and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of furosemide.
Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment.
Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperurecemia and cyclosporine impairment of renal urate excretion.
High doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels.
One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency. There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
The safety and efficacy of SIVEXTRO in patients with neutropenia (neutrophil counts <1000 cells/mm) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes []. Alternative therapies should be considered when treating patients with neutropenia and acute bacterial skin and skin structure infection.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).